FtsA as a cidal target for Staphylococcus aureus: Molecular docking and dynamics studies

TheStaphylococcus aureus‐related infections have been a threat to the mankind for a very long time. Over the period of timeS. aureus strains developed resistance to various antibiotics. The present work focused on developing a novel drug against FtsA, which is very much essential for the survival ofS. aureus. Since it is not found in eukaryotes, there could be potentially no side effects. The ZINC74432848 compound was found to be the best inhibitor ofS. aureus FtsA protein based on docking studies. The simulation study emphasizes the fact that ZINC74432848 compound has a stable interaction withS. aureus FtsA protein. AbstractStaphylococcus aureus infection is a healthcare problem to mankind for a considerable period of time. Once when it enters the bloodstream of an individual, it may potentially result in life ‐threatening conditions. The resistance ofS. aureus to various drugs such as penicillin, methicillin, gentamicin, erythromycin, and tetracycline have been well documented. Presently vancomycin is the drug of choice for methicillin resistantS. aureus. Scientists believe thatS. aureus would completely develop resistance to vancomycin as well. Therefore there is a commensurate need to develop a drug to replace vancomycin. In the current study, we have focussed on FtsA, an important and vital cell division protein, which is found only inS. aureus and in other prokaryotic cells. We have carried out virtual screening process for FtsA against ZINC database, the best hit m...
Source: Journal of Cellular Biochemistry - Category: Biochemistry Authors: Tags: RESEARCH ARTICLE Source Type: research